Papua New Guinea
|DOLF NTDs Present in Papua New Guinea|
Analysis of MDA Frequency in Papua New Guinea
Optimization of Mass Drug Administration with Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea
Study Sites: Dreikikir and Nuku, Papua New Guinea
This study is comparing once annual and twice annual MDA with Dethylcarbamazine and Albendazole for lymphatic filariasis elimination outside of Africa. The first follow-up studies will be completed during 2015 and 2016.
Randomized Trial of Triple Therapy (DEC/Alb/Iver) in Papua New Guinea
Evaluate Triple-Drug Therapy with Diethylcarbamazine (DEC), Albendazole (ALB), and Ivermectin (IVM) that Could Accelerate LF Eliminiation Outside of Africa.
Study Site: Dreikikir, Papua New Guinea
This study is evaluating the effectiveness of the triple drug therapy DEC/Alb/Ivm compared to the standard care treatment of DEC/Alb.
This new regimen has the potential to be a game changer for lymphatic filariasis elimination outside of Africa and in areas of Africa that do not have coendemic loiasis or onchocerciasis.
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis
Clinical Infectious Diseases (2015)
Liquid chromatography–mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic Studies
Journal of Pharmaceutical and Biomedical Analysis 98 (2014) 307–310
Papua New Guinea National Department of Health
Waigani, Papua New Guinea
Leo Makita, Director of Vector Control
Papua New Guinea Institute for Medical Research
Madang, Papua New Guinea
Manesseah Baea, Project Coordinator
Center for Global Health & Disease, Case Western Reserve University
Dr. James Kazura, Director
Dr. Christopher King, Professor of International Health